Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-08-14 19:25Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is facing potential delisting due to significant violations of information disclosure regulations, as identified by the China Securities Regulatory Commission (CSRC) [2][4][10] Group 1: Investigation and Penalties - The company has been under investigation by the CSRC since February 26, 2025, for suspected violations of information disclosure laws [3] - On July 13, 2025, the CSRC issued a notice indicating that the company inflated revenue, costs, and profits from 2020 to 2023, leading to significant discrepancies in financial reporting [4] - The inflated figures included revenue increases of CNY 495.26 million, CNY 468.51 million, CNY 430.75 million, and CNY 376.66 million for the respective years, representing 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues [4] Group 2: Potential Delisting Risks - If the formal penalty decision confirms the violations, the company may face mandatory delisting under the Shanghai Stock Exchange rules [2][5] - The company will apply for a trading suspension and disclose relevant information if it receives a formal penalty decision indicating delisting risks [7] - The stock price closed at CNY 0.99 on August 14, 2025, falling below the CNY 1 threshold, which could also lead to delisting if it remains below this price for 20 consecutive trading days [10][11] Group 3: Compliance and Future Actions - The company is committed to cooperating with the CSRC and will exercise its rights to defend against the allegations [2][5] - The company will continue to fulfill its information disclosure obligations as required by regulations [5][6]